Skip to content

Newleos Therapeutics

7 viewers · 30d

Total raised

$93.4M

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $93.4M
ROUNDS
1
INVESTORS
11
FOUNDED
2024
HQ
Boston, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

Newleos Therapeutics, Inc. is a pioneering clinical-stage neuroscience company focused on the innovation of therapies for neuropsychiatric disorders. With a commitment to addressing the pressing unmet needs in mental health, Newleos is dedicated to developing effective tools for anxiety and substance use disorders, impacting millions across the United States.

What sets it apart

Newleos stands out for its focus on first-in-class therapies that target novel mechanisms, aiming to reduce side effects compared to current treatment options.

Funding history

1 round
EquityFeb 10, 2025
Form D
+$93.4M$93.4M total

Latest SEC filings

via EDGAR · CIK 0002057800
Form D · Feb 10, 2025View on EDGAR

Products

1 tracked

NTX-1955

Mental Health Therapy

NTX-1955 is a groundbreaking GABA A -γ1 selective positive allosteric modulator that represents the company's lead clinical program aimed at treating anxiety disorders. This molecule is designed to help mitigate anxiety symptoms with potentially fewer side effects compared to traditional therapies.

  • First-in-class mechanism targeting GABA A -γ1
  • Oral small molecule formulation
  • Designed with a focus on reducing side effects

Links

WebsiteSEC EDGAR filings